Hip joint distension in osteoarthrosis. A triple-blind controlled study comparing the effect of intra-articular indoprofen with placebo.
In a triple-blind controlled study, significant pain alleviation (p less than 0.01) was registered in patients with osteoarthrosis (OA) of the hip in the first 24 h after hip joint distension. There was no significant difference between treatment with indoprofen (a new non-steroidal anti-inflammatory drug for intra-articular use) and placebo. Pain relief lasted for at least 12 weeks in approximately half of the patients, in whom a significant increase in joint mobility was registered. Intra-articular indoprofen was not superior to placebo as regards pain relief or increased joint mobility. These findings indicate that the effect of a single hip joint distension in OA is due to a mechanical distension of the joint capsule, perhaps involving disruption of local agglutinations, and not due to suppression of inflammation.
D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D005260:Female; D006621:Hip Joint / Q000473:pathology*; D006801:Humans; D007216:Indoprofen / Q000008:administration & dosage / Q000627:therapeutic use*; D007270:Injections, Intra-Articular; D008297:Male; D008875:Middle Aged; D010003:Osteoarthritis / Q000188:drug therapy* / Q000503:physiopathology / Q000628:therapy; D010146:Pain / Q000188:drug therapy / Q000209:etiology; D010666:Phenylpropionates / Q000627:therapeutic use*; D010919:Placebos
D010666:Phenylpropionates; D010919:Placebos; D007216:Indoprofen